Table 3 Treatment-related adverse events.
From: Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients
All grades N = 28 n (%) | Grades 3/4 N = 28 n (%) | |
|---|---|---|
Any event | 26 (92.9) | 12 (42.9) |
Hand-foot skin reaction | 17 (60.7) | 5 (17.9) |
Fatigue | 14 (50.0) | 5 (17.9) |
Weight loss | 12 (42.9) | 4 (14.3) |
Nausea | 7 (25.0) | 2 (7.1) |
Diarrhoea | 11 (39.3) | 2 (7.1) |
Hypertension | 7 (25.0) | 2 (7.1) |
Neuropathy | 2 (7.1) | 2 (7.1) |
Arthralgia | 1 (3.6) | 0 |
Creatinine elevation | 1 (3.6) | 0 |
Liver function tests elevation | 1 (3.6) | 0 |
